文献速递泌尿生殖介入USCTMR

肾脏病灶冷冻消融:术后第1天超声造影增强并不意味着存活组织残留

Cryotherapy of Renal Lesions: Enhancement on Contrast-Enhanced Sonography on Postoperative Day 1 Does Not Imply Viable Tissue Persistence.
PubMed 文献 · J Ultrasound Med · 2016-12-03

研究纳入74例接受经皮肾脏肿瘤冷冻消融的患者,术后第1天行超声造影,以术后6个月CT或MRI为参考标准。术后第1天超声造影显示病灶内增强并不提示肿瘤细胞存活;74例中69例(93%)消融成功。

要点

  • 术后第1天超声造影病灶内增强不能判定为肿瘤残留,需结合术后6个月CT或MRI参考影像。
  • 两位阅片者对早期超声造影病灶血供评估的一致性很好(κ=0.90)。
  • 74例中69例(93%)消融成功,5例参考影像显示残留肿瘤。

核心结论

  • 肾脏肿瘤冷冻消融后,术后第1天超声造影显示的病灶内增强并不意味着肿瘤细胞存活。

研究设计与样本

  • 研究纳入2011年11月至2015年8月间74例经皮肾脏肿瘤冷冻消融并完成术后第1天超声造影的患者;以术后6个月CT或MRI为参考标准评估有无残留病变;两位独立阅片者按4组评分病灶内增强,并用加权κ统计评估阅片者间一致性。

关键影像表现/征象

  • 术后第1天超声造影病灶内增强分为4组:无增强、少量病灶内血管、局灶增强区、弥漫增强。
  • 74例中两位阅片者均判定33例无增强,21例仅见少量病灶内血管,13例见弥漫或局灶增强,其余7例两位阅片者判断不一致。
  • 术后第1天超声造影显示局灶增强的4个病灶及被判为无血管的1个病灶,在参考影像上显示残留肿瘤。

诊断标准与关键数值

  • 以术后6个月CT或MRI显示的残留增强组织为参考标准,判定存在残留存活肿瘤。
  • 两位阅片者评估术后第1天超声造影病灶内血管化的加权κ=0.90。
  • 74例中69例(93%)消融成功。

临床应用与阅片要点

  • 阅片时应注意术后第1天超声造影出现病灶内增强并不能直接判读为肿瘤残留。
  • 对术后第1天超声造影显示增强的病灶,原文在术后1个月复查超声造影,并结合术后6个月CT或MRI参考影像评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate whether persistent enhancement detected on contrast-enhanced sonography at postoperative day 1 (early contrast-enhanced sonography) after cryoablation of renal tumors implies the presence of residual viable tumor tissue, defined as residual enhancing tissue on reference imaging (computed tomography or magnetic resonance imaging) performed 6 months after the procedure.

METHODS: Seventy-four patients with percutaneous cryoablation of renal tumors had early contrast-enhanced sonography from November 2011 to August 2015. Two independent readers evaluated early contrast-enhanced sonographic findings and contrast-enhanced sonographic investigations performed 1 month after cryoablation of lesions that displayed enhancement on early contrast-enhanced sonography. They scored intralesional enhancement in 4 groups: no enhancement, few intralesional vessels, focal enhancing areas, and diffuse enhancement. Inter-reader agreement in evaluating lesion vascularity on early contrast-enhanced sonography was assessed with weighted κ statistics. Computed tomography or magnetic resonance imaging performed 6 months after the treatment was the reference procedure for assessing the absence or presence of residual disease.

RESULTS: Inter-reader agreement in assessing intratumoral vascularization on early contrast-enhanced sonography was very good (κ = 0.90). Enhancement was absent for both readers in 33 of 74 cases; only a few intralesional vessels were visible in 21; whereas diffuse or focal enhancement was present in 13. In the remaining 7 patients, there were differences. Four lesions with focal enhancement on early contrast-enhanced sonography and 1 that was considered avascular had residual tumors on reference imaging. Ablation was successful in the remaining 69 of 74 patients (93%).

CONCLUSIONS: After cryoablation, intratumoral enhancement on early contrast-enhanced sonography does not imply tumor cell viability.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Bertolotto M, Siracusano S, Cicero C, et al. Cryotherapy of Renal Lesions: Enhancement on Contrast-Enhanced Sonography on Postoperative Day 1 Does Not Imply Viable Tissue Persistence. J Ultrasound Med. 2016. PMID: 27914172. doi:10.7863/ultra.16.02061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。